Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Almac Group
Private Company Edition: Omega Funds closed its seventh venture capital fund, far exceeding its $500m goal. Also, Anaveon raised a CHF110m ($119.8m) series B round, Ambys brought its series A total to $107m with $47m in additional investment and Mythic launched with a $103m series B round.
Plus deals involving Sun's SPARC/Visiox, Twist/Sosei, BeiGene, Leads Biolabs, Qilu/Arbutus, Hansoh/Keros, Simcere/Avilex and Cytokinetics/Ji Xing.
Pfizer's Erik Nordkamp has been named as the new president of the Association of the British Pharmaceutical Industry. Vant, Grail, Acceleron, Kite, Nimbus, Biophytis, Orchard Therapeutics, G1 Therapeutics, Almac Discovery, Athenex and Sunesis have also made key appointments.
BIO Notebook Day 4: Gottlieb Seeks Early Engagement On Gene Therapy; Ireland’s Brexit Opportunities; AMAG’s Bremelanotide Strategy; Alzheimer’s ‘Learnings’
US FDA to head off cell/gene therapy manufacturing issues with pre-IND meetings; Republic of Ireland will “chase any opportunities” for business partners stemming from Brexit, even while hoping UK reconsiders EU departure; AMAG won’t follow the flibanserin PR approach with newly submitted female sexual dysfunction drug bremelanotide; United Neuroscience CMO Ajay Verma says Alzheimer’s trial setbacks are “learnings,” with progress toward novel therapies moving faster than it has for cancer and HIV.
- Contract Research Organization-CRO
- Contract Manufacturing Organization
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
Drug Discovery Tools
- Other Names / Subsidiaries
- Almac Diagnostic Services
- Almac Discovery
- Galen Limited BioClin Laboratories Arran Chemical Company